Reata Pharmaceuticals Inc Quick Ratio (RETA) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Reata Pharmaceuticals Inc   (NASDAQ: RETA)

Reata Pharmaceuticals Inc 's Quick Ratio

RETA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2023, Quick Ratio fell to 2.64 below Reata Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 341 other companies have achieved higher Quick Ratio than Reata Pharmaceuticals Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 590 to 1240.

Explain Quick Ratio?
How much Cash & cash equivalents RETA´s has?
What are RETA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RETA Quick Ratio (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2
Y / Y Current Liabilities Change 257.28 % 25.17 % 9.2 % -58.19 % -71.09 %
Y / Y Cash & cash equivalent Change -31.42 % -39.67 % -34.35 % -38.89 % -36.29 %
Quick Ratio MRQ 2.64 5.88 6.57 8.6 13.75
RETA's Total Ranking # 1240 # 590 # 592 # 458 # 244
Seq. Current Liabilities Change 129.12 % -7.4 % 16.27 % 44.83 % -19.73 %
Seq. Cash & cash equivalent Change 2.88 % -17.17 % -11.1 % -9.47 % -9.49 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 342
Healthcare Sector # 593
Overall Market # 1240


Quick Ratio Statistics
High Average Low
14.36 6.46 1.27
(Jun 30 2020)   (Jun 30 2017)




Financial Statements
Reata Pharmaceuticals Inc 's Current Liabilities $ 125 Millions Visit RETA's Balance sheet
Reata Pharmaceuticals Inc 's Cash & cash equivalent $ 330 Millions Visit RETA's Balance sheet
Source of RETA's Sales Visit RETA's Sales by Geography


Cumulative Reata Pharmaceuticals Inc 's Quick Ratio

RETA's Quick Ratio for the trailling 12 Months

RETA Quick Ratio

 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 13.96 % -41.39 % -54.16 % -51.18 % -14.32 %
Y / Y Cash & cash equivalent TTM Growth -36.36 % -37.26 % -35.25 % -33.45 % -20.92 %
Quick Ratio TTM 5.1 8.16 9.75 11.12 9.12
Total Ranking TTM # 1745 # 1192 # 653 # 389 # 443
Seq. Current Liabilities TTM Growth 45.2 % 5.83 % 2.71 % -27.79 % -25.32 %
Seq. Cash & cash equivalent TTM Growth -9.3 % -11.49 % -9.94 % -11.97 % -10.58 %

Quick ratio ranking by company, industry and sector >> Back to RETA Financial Strength Comparisons >> Go to Compare RETA Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2023 to $125.09 millions, cumulative Quick Ratio decreased to 5.1 above the RETA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 542 other companies have achieved higher Quick Ratio than Reata Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 3384 to 4133.

Explain Quick Ratio?
How much Cash & cash equivalents RETA´s has?
What are RETA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 543
Healthcare Sector # 1103
Within the Market # 1240


trailing twelve months Quick Ratio Statistics
High Average Low
8.5 4.27 0.72
(Mar 31 2021)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
Metavia Inc   7.20 $ 28.688  Millions$ 3.983  Millions
Bolt Biotherapeutics Inc   7.14 $ 125.866  Millions$ 17.618  Millions
Clearside Biomedical Inc   7.12 $ 35.005  Millions$ 4.915  Millions
Cormedix Inc   7.09 $ 52.401  Millions$ 7.387  Millions
Puretech Health Plc  7.05 $ 362.261  Millions$ 51.370  Millions
Opus Genetics Inc   6.94 $ 39.999  Millions$ 5.761  Millions
Theravance Biopharma inc   6.82 $ 167.451  Millions$ 24.546  Millions
Ngm Biopharmaceuticals Inc   6.81 $ 193.544  Millions$ 28.423  Millions
Oragenics Inc   6.81 $ 6.474  Millions$ 0.951  Millions
Sagimet Biosciences inc   6.80 $ 18.508  Millions$ 2.723  Millions
Assembly Biosciences Inc   6.78 $ 59.831  Millions$ 8.831  Millions
Calcimedica Inc   6.77 $ 19.084  Millions$ 2.817  Millions
Hoth Therapeutics Inc   6.74 $ 11.569  Millions$ 1.716  Millions
Context Therapeutics Inc   6.70 $ 25.138  Millions$ 3.750  Millions
Abcellera Biologics Inc   6.69 $ 795.694  Millions$ 118.905  Millions
Cohbar Inc   6.57 $ 12.311  Millions$ 1.874  Millions
Carisma Therapeutics Inc   6.51 $ 117.078  Millions$ 17.973  Millions
Ardelyx inc   6.50 $ 255.158  Millions$ 39.226  Millions
Chinook Therapeutics Inc   6.50 $ 297.165  Millions$ 45.704  Millions
Tff Pharmaceuticals Inc  6.31 $ 7.663  Millions$ 1.215  Millions
Sol gel Technologies Ltd   6.27 $ 36.563  Millions$ 5.835  Millions
Incannex Healthcare Inc  6.25 $ 55.483  Millions$ 8.877  Millions
Marker Therapeutics inc   6.20 $ 18.122  Millions$ 2.921  Millions
Gracell Biotechnologies Inc   6.13 $ 163.833  Millions$ 26.728  Millions
Immunogen inc   6.10 $ 571.987  Millions$ 93.702  Millions
Neuphoria Therapeutics Inc   6.10 $ 25.184  Millions$ 4.129  Millions
Kala Bio inc   6.01 $ 59.178  Millions$ 9.851  Millions
Novabridge Biosciences  5.89 $ 321.788  Millions$ 54.610  Millions
Applied Molecular Transport Inc   5.88 $ 22.457  Millions$ 3.816  Millions
Roivant Sciences Ltd   5.85 $ 1,434.093  Millions$ 245.004  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.